AAA financials reveal 30% uptick in sales

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Advanced Accelerator Applications (AAA) in Saint-Genis-Pouilly, France, announced yesterday that the company’s sales were up just over 30 percent to almost $80 million, according to an annual financial report.

The company’s big news this year is an ongoing phase III trial for Lu-DOTATATE (Lutathera) and ongoing development of Ga-68 DOTATATE (Somakit), which obtained both FDA and EMA orphan drug designation, and Tc-99m rh-Annexin V-128, for the visualization of apoptosis in oncologic applications.

Stefano Buono, chief executive officer of AAA, told Molecular Imaging, “GEP-NETs constitute a life-threatening disease and effective patient management requires accurate diagnostic tools. The orphan drug designation of AAA’s Gallium-68 DOTATATE will accelerate the development of this agent and hopefully allow it to be available to patients in the next few years. ”

The company also reported expansion in both Europe and the U.S., a capital increase of more than $55 million. Most notably the company established AAA Poland and signed an agreement with the University of Warsaw for a new production site.

Non-executive directors Yvonne Greenstreet, Steven Gannon, Christian Merle and Leopoldo Zambeletti have been added to AAA’s board.

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.